Immune-related Bell’s palsy in melanoma patients treated with immune checkpoint inhibitorsTeresa Beninato, Carolina Cimminiello, Barbara Valeri et al.|Melanoma Research|2021Cited by 5
Risk of disease progression (PD) following discontinuation of BRAF±MEK targeted therapies for reasons other than PD in patients (pts) with metastatic or unresectable melanoma.Francesca Corti, Lorenza Di Guardo, Giovanni Randon et al.|Journal of Clinical Oncology|2020Cited by 4